Publications

Back to Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

Following approval of belimumab (based on the results of the BLISS-LN study) in the United States and Europe, as the first biologic agent for the treatment of adult patients with active lupus nephritis, Furie, et al. investigate adding or continuing belimumab treatment beyond 2 years, in this open-label extension study.

Keywords:


LinkedIn